Skip to main content
Home

oAv Menu

  • Home
  • Patient Care Center
  • Clinical Trials
  • Providers
    • Therapeutics
    • People
    • Places
  • Community Center
    • Community Stories
    • Social Media
    • Community Content
    • Financial Assistance
  • News
    • Community Events
    • Clinical Trials and Research
    • Business
    • News People
    • Happenings
    • Spotlight
    • Fundraising Events
  • Trusted Resources
    • Education
    • Videos & Visuals
  • Event Calendar
  • Login
  • Search
amyloidosis
ATTR-CM outcomes differ by sex, but biology may not explain why
Jul 30, 2026

News

sciencedirect
Indication and electrical performance of conventional, resynchronization, and conduction system pacing in transthyretin amyloid cardiomyopathy
Jul 30, 2026
pubmed
Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial
Jul 29, 2026
amyloidosis
Acoramidis Attenuates Decline in Heart Failure–Related Health Status in ATTR-CM
Jul 29, 2026
medscape
Tafamidis Generic Wins EU Backing for ATTR Cardiomyopathy
Jul 28, 2026
JACC Journals
Sex Differences in Presentation and Outcomes of Transthyretin Amyloid Cardiomyopathy
Jul 28, 2026
More in News

Education

amyloidosis
ATTR-CM outcomes differ by sex, but biology may not explain why
Jul 30, 2026
amyloidosis
Cardiac Amyloidosis: Diagnosis, Outlook, and Modern Treatment Approaches
Jul 29, 2026
droracle
How should I work up a patient with suspected amyloidosis that has not yet been diagnosed?
Jul 28, 2026
ASH Publications
American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis
Jul 28, 2026
Rare Disease Advisor.
ATTR-CM: Earlier Diagnosis Reshapes Treatment Expectations
Jul 27, 2026
More in Education

Community Center

amyloidosis
BU Amyloidosis Center
Jul 30, 2026
amyloidosis
From the Gridiron to the Clinic: A Former Chiefs Player Battles Amyloidosis with Expert Care
Jul 30, 2026
amyloidosis
Kenneth Civello MD, MPH’s Post
Jul 30, 2026
amyloidosis
What are the symptoms and experiences of wild-type Amyloidosis patients?
Jul 30, 2026
amyloidosis
Prof. Dr. med. Christoph Gräni’s Post
Jul 29, 2026
More in Community Center

Video

Newsletter

Stay informed - subscribe to our newsletter.
The subscriber's email address.

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Learn More

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion

Featured Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis
Molecular Imaging of Primary Amyloid Cardiomyopathy

Footer menu

  • Home
  • About us
  • Video
  • Galleries
  • Contact
  • Login
  • Privacy Policy
  • Privacy Reminder
  • Terms of use
  • FAQ
  • Code of Conduct

© 2025 Somebody To Talk To, Inc.

Join us on                     
Alnylam Logo external link, opens in a new tabPfizer Logo external link, opens in a new tabBridgebio Logo external link, opens in a new tabAttralus Logo external link, opens in a new tabProthena Logo external link, opens in a new tab
Amyloidosis Foundation Logo external link, opens in a new tab